Vietnam Veterans Liver Fluke Cancer Study Act

Hozzl · 2025-04-10T01:53:17Z

Explore the details of House Bill 586 Vietnam Veterans Liver Fluke Cancer Study Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Armed Forces and National Security. Stay informed on legislative developments.

4/10/2025, 1:53 AM

Summary of Bill HR 586

Bill 119 hr 586, also known as the Cholangiocarcinoma Study Act, aims to address the prevalence of cholangiocarcinoma, a rare form of cancer, in veterans who served in the Vietnam theater of operations during the Vietnam era. The bill directs the Secretary of Veterans Affairs to conduct a study and report on the occurrence of this cancer among Vietnam veterans.

The study will focus on gathering data and information on the number of cases of cholangiocarcinoma among Vietnam veterans, as well as any potential risk factors or causes of the disease. The goal is to better understand the impact of military service on the health of these veterans and to provide them with the necessary support and resources.

In addition to studying the prevalence of cholangiocarcinoma, the bill also aims to identify any potential treatments or interventions that may be beneficial for veterans who have been diagnosed with this cancer. By conducting this study, the Secretary of Veterans Affairs will be able to provide valuable information to healthcare providers and researchers, ultimately improving the care and support available to Vietnam veterans. Overall, the Cholangiocarcinoma Study Act seeks to address a pressing health issue among Vietnam veterans and to ensure that they receive the care and attention they deserve.

Congressional Summary of HR 586

Vietnam Veterans Liver Fluke Cancer Study Act

This bill requires the Department of Veterans Affairs (VA) to conduct an epidemiological study and report on the prevalence of cholangiocarcinoma (bile duct cancer) in veterans who served in the Vietnam theater of operations during the Vietnam era. The study must identify the rate of incidence of cholangiocarcinoma in such veterans and in U.S. residents.

The bill also requires the VA to track and report on the prevalence of cholangiocarcinoma using the Veterans Affairs Central Cancer Registry. Additionally, the VA must periodically submit follow-up reports to Congress regarding the epidemiological study and information collected from the cancer registry regarding the prevalence of bile duct cancer.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 586

Bill HR 586 is currently in the status of Introduced to Senate since April 8, 2025. Bill HR 586 was introduced during Congress 119 and was introduced to the House on January 21, 2025. Bill HR 586's most recent activity was Received in the Senate and Read twice and referred to the Committee on Veterans' Affairs. as of April 8, 2025

Bipartisan Support of Bill HR 586

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 586

Primary Policy Focus

Armed Forces and National Security

Potential Impact Areas

AsiaCancerConflicts and warsCongressional oversightGovernment studies and investigationsHealth information and medical recordsMedical researchVeterans' medical careVietnam

Alternate Title(s) of Bill HR 586

To direct the Secretary of Veterans Affairs to study and report on the prevalence of cholangiocarcinoma in veterans who served in the Vietnam theater of operations during the Vietnam era, and for other purposes.To direct the Secretary of Veterans Affairs to study and report on the prevalence of cholangiocarcinoma in veterans who served in the Vietnam theater of operations during the Vietnam era, and for other purposes.

Start holding our government accountable!